Current uses and outcomes of hematopoietic stem cell transplantation 2012
This presentation is the property of its rightful owner.
Sponsored Links
1 / 44

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 PowerPoint PPT Presentation


  • 111 Views
  • Uploaded on
  • Presentation posted in: General

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012. Summary Slides. SUM12_1.ppt. Location of Centers Participating in the CIBMTR 2012. Slide 2. SUM12_22.ppt. Transplant Activity in the U.S. 1980-2011. Transplants. Slide 3. SUM12_23.ppt.

Download Presentation

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation2012

Summary Slides

SUM12_1.ppt


Location of centers participating in the cibmtr 2012

Location of Centers Participating in the CIBMTR2012

Slide 2

SUM12_22.ppt


Transplant activity in the u s 1980 2011

Transplant Activity in the U.S.1980-2011

Transplants

Slide 3

SUM12_23.ppt


Allogeneic stem cell sources by recipient age 2001 2010

Allogeneic Stem Cell Sourcesby Recipient Age2001-2010

Transplants, %

Age £ 20 yrsAge > 20 yrs

Slide 4

SUM12_24.ppt


Autologous stem cell sources by recipient age 2001 2010

Autologous Stem Cell Sourcesby Recipient Age, 2001-2010

Transplants, %

Age £ 20 yrsAge > 20 yrs

Slide 5

SUM12_25.ppt


Trends in transplants by type and recipient age 2001 2010

Trends in Transplantsby Type and Recipient Age*2001-2010

Transplants, %

Allogeneic TransplantsAutologous Transplants

* Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma

Slide 6

SUM12_26.ppt


Trends in transplants by transplant type and recipient age 1990 2010

Trends in Transplantsby Transplant Type and Recipient Age*1990-2010

Transplants, %

Allogeneic TransplantsAutologous Transplants

* Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma

Slide 7

SUM12_27.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Indications for Hematopoietic Stem Cell Transplants in the United States, 2010(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants)

Number of Transplants

Slide 8

SUM12_28.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Indications for Hematopoietic Stem Cell Transplants for Age £ 20yrs, in the U.S., 2010(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants)

Number of Transplants

Slide 9

SUM12_29.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Allogeneic Transplants for Age £ 20yrs,Registered with the CIBMTR, 1993-2010- by Donor Type and Graft Source -

Number of Transplants

Slide 10

SUM12_30.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Allogeneic Transplants for Age > 20yrs,Registered with the CIBMTR, 1993-2010- by Donor Type and Graft Source -

Number of Transplants

Slide 11

SUM12_31.ppt


Unrelated donor stem cell sources by recipient age 2001 2010

Unrelated Donor Stem Cell Sourcesby Recipient Age2001-2010

Transplants, %

Age £ 20 yrsAge > 20 yrs

Slide 12

SUM12_32.ppt


Unrelated cord blood transplants by age registered with the cibmtr 2001 2010

Unrelated Cord Blood Transplants by AgeRegistered with the CIBMTR2001-2010

Number of Transplants

*

* Data incomplete

Slide 13

SUM12_33.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

One-year Survivalby Year of Transplant, Donor and Age, Worldwide, 1997-2010- In any remission, Acute Leukemia, CML or MDS-

One-Year Survival, %

Slide 14

SUM12_34.ppt


100 day mortality after autologous transplants 2010

100-day Mortality after Autologous Transplants, 2010

Mortality, %

Slide 15

SUM12_35.ppt


100 day mortality after hla identical sibling transplants 2010

100-day Mortality after HLA-identical Sibling Transplants,2010

Early Disease

Intermediate Disease

Advanced Disease

Chronic Phase

Accelerated Phase

Blast Phase

Other

Mortality, %

Slide 16

SUM12_36.ppt


100 day mortality after unrelated donor transplants 2008 2009

100-day Mortality after Unrelated Donor Transplants,2008-2009

Early Disease

Intermediate Disease

Advanced Disease

Chronic Phase

Accelerated Phase

Blast Phase

Other

Mortality, %

Slide 17

SUM12_37.ppt


Causes of death after transplants done in 2009 2010

Causes of Death after Transplants Done in2009-2010

HLA-identical Sibling

Primary Disease (49%)

New Malignancy (1%)

GVHD (16%)

Unrelated Donor

Infection (13%)

Primary Disease

(37%)

New Malignancy (1%)

Organ Failure (5%)

Other (16%)

GVHD (18%)

Autologous

Primary Disease (72%)

New Malignancy (1%)

Infection (7%)

Infection (18%)

Other (18%)

Organ Failure (3%)

Organ Failure (8%)

Other (17%)

Slide 18

SUM12_38.ppt


Allogeneic transplants registered with the cibmtr 2001 2010 by conditioning regimen intensity age

Allogeneic TransplantsRegistered with the CIBMTR, 2001-2010 - by Conditioning Regimen Intensity & Age -

Number of Transplants

*

* Data incomplete

Slide 19

SUM12_39.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Allogeneic Transplants after Reduced-intensity Conditioning, by Donor Type, Registered with CIBMTR1998-2010

Number of Transplants

Slide 20

SUM12_40.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Percentage of Reduced Intensity Conditioning Allo-HCTs, Registered with CIBMTR, 1998-2010- by Year of Transplant & Disease -

Reduced Intensity Conditioning,%

Slide 21

SUM12_41.ppt


Indications for hematopoietic stem cell transplants for age 5 0yrs in the u s 2010

Indications for Hematopoietic Stem Cell Transplants for Age ³ 50yrs, in the U.S., 2010

Number of Transplants

Slide 22

SUM12_42.ppt


Allogeneic transplants in the u s registered with the cibmtr 2007 2011 by donor type

Allogeneic Transplants in the U.S.,Registered with the CIBMTR, 2007-2011 - by Donor Type -

Transplants, %

Slide 23

SUM12_43.ppt


Hematopoietic cell transplant comorbid index of u s transplant recipients by group age 2008 2011

Hematopoietic Cell Transplant Comorbid Index of U.S. Transplant Recipientsby Group Age2008-2011

Transplants, %

Slide 24

SUM12_44.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Probability of Survival after HLA-identical Sibling Donor Transplants for AML, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

60

60

Early (N=7,210)

Probability of Survival, %

50

50

40

40

Intermediate (N=1,906)

30

30

20

20

Advanced (N=2,923)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 25

SUM12_2.ppt


Probability of survival after unrelated donor transplants for aml 2000 2010 by disease status

Probability of Survival after Unrelated Donor Transplants for AML, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

60

60

Probability of Survival, %

50

50

Early (N=5,364)

40

40

Intermediate (N=3,374)

30

30

20

20

Advanced (N=3.702)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 26

SUM12_3.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Survival after HLA-identical Sibling Donor Transplants for AML, Age <20 yrs, 2000-2010- by Disease Status -

100

100

90

90

80

80

70

70

Early (N=1,292)

60

60

Probability of Survival, %

50

50

Intermediate (N=268)

40

40

30

30

Advanced (N=270)

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 27

SUM12_4.ppt


Probability of survival after autologous transplants for aml 2000 2010 by disease status

Probability of Survival after Autologous Transplants for AML, 2000-2010- by Disease Status -

100

100

90

90

80

80

70

70

60

60

Intermediate (N=735)

Probability of Survival, %

50

50

40

40

Early (N=2,139)

30

30

20

20

Advanced (N=152)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 28

SUM12_5.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Probability of Survival after Allogeneic Transplants for MDS, 2000-2010- by Disease Status and Donor Type -

100

100

90

90

80

80

70

70

Early, sibling donor (N=750)

60

60

Early, unrelated

donor (N=890)

Probability of Survival, %

50

50

40

40

Advanced, unrelated donor (N=1,660)

30

30

20

20

Advanced, sibling donor (N=1,407)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 29

SUM12_6.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Survival after HLA-identical Sibling Donor Transplants for ALL, Age < 20 yrs,2000-2010- by Disease Status -

100

100

90

90

80

80

70

70

Early (N=849)

60

60

Probability of Survival, %

50

50

Intermediate (N=1,203)

40

40

30

30

20

20

Advanced (N=210)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 30

SUM12_7.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Probability of Survival after Unrelated Donor Transplants for ALL, Age < 20 yrs, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

Early (N=977)

60

60

Probability of Survival, %

50

50

40

40

Intermediate (N=2,034)

30

30

20

20

Advanced (N=289)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 31

SUM12_8.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Survival after HLA-identical Sibling Donor Transplants for ALL, Age ³ 20 yrs, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

60

60

Early (N=2,214)

Probability of Survival, %

50

50

40

40

Intermediate (N=715)

30

30

20

20

Advanced (N=584)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 32

SUM12_9.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Probability of Survival after Unrelated Donor Transplants for ALL, Age ³ 20 yrs, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

60

60

Early (N=1,818)

Probability of Survival, %

50

50

40

40

30

30

Intermediate (N=1,075)

20

20

10

10

Advanced (N=767)

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 33

SUM12_10.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Probability of Survival after HLA-identical Sibling Donor Transplants for CML, 1998-2010- By Disease Status and Transplant Year -

100

100

90

90

80

80

CP, 2001-2010 (N=2,498)

70

70

CP, 1998-2000 (N=2,239)

60

60

AP, 2001-2010 (N=360)

Probability of Survival, %

50

50

40

40

AP, 1998-2000 (N=291)

30

30

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 34

SUM12_11.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Survival after Autologous and HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL, 2000-2010- by Donor Type and Conditioning Regimen Intensity -

100

100

90

90

Autologous transplant (N=270)

80

80

70

70

60

60

Probability of Survival, %

50

50

Myeloablativeconditioning (N=450)

40

40

Reduced-intensity conditioning (N=871)

30

30

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 35

SUM12_12.ppt


Probability of survival after allogeneic transplants for saa 2000 2010 by donor type and age

Probability of Survival after Allogeneic Transplants for SAA, 2000-2010- By Donor Type and Age -

100

100

£ 20y, Sibling Donor (N=1,375)

90

90

80

80

> 20y, Sibling Donor (N=1,425)

70

70

£ 20y, Unrelated Donor (N=654)

60

60

> 20y, Unrelated Donor (N=634)

Probability of Survival, %

50

50

40

40

30

30

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 36

SUM12_13.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Probability of Survival after Autologous Transplants for Hodgkin Disease, 2000-2010- By Disease Status -

100

100

90

90

CR (N=2,907)

80

80

70

70

60

60

Not in CR, sensitive (N=3,832)

Probability of Survival, %

50

50

Not in CR, resistant (N=1,237)

40

40

30

30

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 37

SUM12_14.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Probability of Survival after Allogeneic Transplants for Hodgkin Disease, 2000-2010- By Conditioning Regimen and Donor Type -

100

100

90

90

80

80

70

70

60

60

Probability of Survival, %

50

50

Sibling Donor (N=356)

40

40

30

30

Unrelated Donor (N=205)

20

20

10

10

P = 0.226

0

0

1

3

0

2

4

5

6

Years

Slide 38

SUM12_15.ppt


Survival after autologous transplants for follicular lymphoma 2000 2010 by disease status

Survival after Autologous Transplants for Follicular Lymphoma, 2000-2010- By Disease Status -

100

100

90

90

80

80

Sensitive (N=2,676)

70

70

60

60

Probability of Survival, %

50

50

Resistant (N=279)

40

40

30

30

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 39

SUM12_16.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Probability of Survival after Allogeneic and HLA-identical Sibling Transplants for Follicular Lymphoma, 2000-2010- By Disease Status -

100

100

90

90

80

80

Sensitive (N=840)

70

70

60

60

Probability of Survival, %

50

50

Resistant (N=212)

40

40

30

30

20

20

10

10

P = 0.002

0

0

1

3

0

2

4

5

6

Years

Slide 40

SUM12_17.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Probability of Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

Sensitive (N=8,891)

60

60

Probability of Survival, %

50

50

40

40

30

30

Resistant (N=1,033)

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 41

SUM12_18.ppt


Current uses and outcomes of hematopoietic stem cell transplantation 2012

Probability of Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010- By Disease Status -

100

100

90

90

80

80

70

70

60

60

Probability of Survival, %

50

50

Sensitive (N=503)

40

40

30

30

20

20

Resistant (N=219)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 42

SUM12_19.ppt


Probability of survival after transplants for mantle cell lymphoma 2000 2010 by donor type

Probability of Survival after Transplants for Mantle Cell Lymphoma, 2000-2010- By Donor Type -

100

100

90

90

80

80

70

70

Autologous (3,173)

60

60

Probability of Survival, %

50

50

Sibling donor (N=554)

40

40

30

30

Unrelated donor (N=389)

20

20

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 43

SUM12_20.ppt


Probability of survival after transplants for multiple myeloma 2000 2010 by donor type

Probability of Survival after Transplants for Multiple Myeloma, 2000-2010- By Donor Type -

100

100

90

90

80

80

Autologous (N27,979)

70

70

60

60

Probability of Survival, %

50

50

40

40

Sibling Donor (N=892)

30

30

20

20

Unrelated donor (N=380)

10

10

P < 0.0001

0

0

1

3

0

2

4

5

6

Years

Slide 44

SUM12_21.ppt


  • Login